BACKGROUND: The World Health Organization (WHO) HIV drug resistance (HIVDR) threshold survey method was developed for surveillance of transmitted HIVDR in resource-limited countries. The method is being implemented with minimal resources as a routine public health activity to produce comparable results in multiple countries and areas within countries. Transmitted drug resistant HIV strains will be seen first in cities or health districts where antiretroviral treatment (ART) has been widely available for years. WHO recommends countries begin surveillance in these areas. METHODS: Each survey requires < or =47 specimens from individuals consecutively diagnosed with HIV to categorize resistance to each relevant drug class as <5%, 5-15% or >15%. Use of routinely collected information and remnant specimens is recommended to minimize costs. Site and individual eligibility criteria are designed to minimize inclusion of ARV-experienced individuals and individuals infected before ART was available. RESULTS: Surveys have been implemented in 21 countries. In this supplement, seven countries report results of <5% transmitted HIVDR in areas where ART has been available for the longest time period. The main challenges in implementation are acquiring sufficient numbers of eligible specimens and optimizing specimen handling. CONCLUSION: The WHO HIVDR threshold survey method is feasible in resource-limited countries and produces information relevant to ART and drug resistance prevention planning.
BACKGROUND: The World Health Organization (WHO) HIV drug resistance (HIVDR) threshold survey method was developed for surveillance of transmitted HIVDR in resource-limited countries. The method is being implemented with minimal resources as a routine public health activity to produce comparable results in multiple countries and areas within countries. Transmitted drug resistant HIV strains will be seen first in cities or health districts where antiretroviral treatment (ART) has been widely available for years. WHO recommends countries begin surveillance in these areas. METHODS: Each survey requires < or =47 specimens from individuals consecutively diagnosed with HIV to categorize resistance to each relevant drug class as <5%, 5-15% or >15%. Use of routinely collected information and remnant specimens is recommended to minimize costs. Site and individual eligibility criteria are designed to minimize inclusion of ARV-experienced individuals and individuals infected before ART was available. RESULTS: Surveys have been implemented in 21 countries. In this supplement, seven countries report results of <5% transmitted HIVDR in areas where ART has been available for the longest time period. The main challenges in implementation are acquiring sufficient numbers of eligible specimens and optimizing specimen handling. CONCLUSION: The WHO HIVDR threshold survey method is feasible in resource-limited countries and produces information relevant to ART and drug resistance prevention planning.
Authors: Nellie Wadonda-Kabondo; Bethany L Hedt; Joep J van Oosterhout; Kundai Moyo; Eddie Limbambala; George Bello; Ben Chilima; Erik Schouten; Anthony Harries; Moses Massaquoi; Carol Porter; Ralf Weigel; Mina Hosseinipour; John Aberle-Grasse; Michael R Jordan; Storn Kabuluzi; Diane E Bennett Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Nellie Wadonda-Kabondo; Richard Banda; Kundai Moyo; Maurice M'bang'ombe; Mabvuto Chiwaula; Carol Porter; Michael R Jordan Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Cyrille F Djoko; Nathan D Wolfe; Nicole Vidal; Ubald Tamoufe; Celine Montavon; Matthew LeBreton; Brian L Pike; Joseph Fair; Wilfred F Mbacham; Alogos Benito; Anne W Rimoin; Karen Saylors; Eitel Mpoudi-Ngole; Michael P Grillo; Martine Peeters Journal: AIDS Res Hum Retroviruses Date: 2010-09 Impact factor: 2.205
Authors: Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong Journal: Clin Microbiol Rev Date: 2018-11-28 Impact factor: 26.132